These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29485874)

  • 1. Creation of a Novel Class of Potent and Selective MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based Screening and Structure-Based Drug Design.
    Rahm F; Viklund J; Trésaugues L; Ellermann M; Giese A; Ericsson U; Forsblom R; Ginman T; Günther J; Hallberg K; Lindström J; Persson LB; Silvander C; Talagas A; Díaz-Sáez L; Fedorov O; Huber KVM; Panagakou I; Siejka P; Gorjánácz M; Bauser M; Andersson M
    J Med Chem; 2018 Mar; 61(6):2533-2551. PubMed ID: 29485874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target.
    Ellermann M; Eheim A; Rahm F; Viklund J; Guenther J; Andersson M; Ericsson U; Forsblom R; Ginman T; Lindström J; Silvander C; Trésaugues L; Giese A; Bunse S; Neuhaus R; Weiske J; Quanz M; Glasauer A; Nowak-Reppel K; Bader B; Irlbacher H; Meyer H; Queisser N; Bauser M; Haegebarth A; Gorjánácz M
    ACS Chem Biol; 2017 Aug; 12(8):1986-1992. PubMed ID: 28679043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival.
    Kettle JG; Alwan H; Bista M; Breed J; Davies NL; Eckersley K; Fillery S; Foote KM; Goodwin L; Jones DR; Käck H; Lau A; Nissink JW; Read J; Scott JS; Taylor B; Walker G; Wissler L; Wylot M
    J Med Chem; 2016 Mar; 59(6):2346-61. PubMed ID: 26878898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of potent and selective MTH1 inhibitors.
    Petrocchi A; Leo E; Reyna NJ; Hamilton MM; Shi X; Parker CA; Mseeh F; Bardenhagen JP; Leonard P; Cross JB; Huang S; Jiang Y; Cardozo M; Draetta G; Marszalek JR; Toniatti C; Jones P; Lewis RT
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1503-1507. PubMed ID: 26898335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and structure-activity relationship of purine derivatives as novel MTH1 inhibitors.
    Kumar A; Kawamura T; Kawatani M; Osada H; Zhang KYJ
    Chem Biol Drug Des; 2017 Jun; 89(6):862-869. PubMed ID: 27863017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a new class of MTH1 inhibitor by X-ray crystallographic screening.
    Yokoyama T; Kitakami R; Mizuguchi M
    Eur J Med Chem; 2019 Apr; 167():153-160. PubMed ID: 30771603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity.
    Peng C; Li YH; Yu CW; Cheng ZH; Liu JR; Hsu JL; Hsin LW; Huang CT; Juan HF; Chern JW; Cheng YS
    Bioorg Chem; 2021 May; 110():104813. PubMed ID: 33774493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.
    Huber KV; Salah E; Radic B; Gridling M; Elkins JM; Stukalov A; Jemth AS; Göktürk C; Sanjiv K; Strömberg K; Pham T; Berglund UW; Colinge J; Bennett KL; Loizou JI; Helleday T; Knapp S; Superti-Furga G
    Nature; 2014 Apr; 508(7495):222-7. PubMed ID: 24695225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent and specific MTH1 inhibitors targeting gastric cancer.
    Zhou W; Ma L; Yang J; Qiao H; Li L; Guo Q; Ma J; Zhao L; Wang J; Jiang G; Wan X; Adam Goscinski M; Ding L; Zheng Y; Li W; Liu H; Suo Z; Zhao W
    Cell Death Dis; 2019 Jun; 10(6):434. PubMed ID: 31164636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic therapy of chemotherapeutic drugs and MTH1 inhibitors using a pH-sensitive polymeric delivery system for oral squamous cell carcinoma.
    Li X; Li L; Huang Y; Liu B; Chi H; Shi L; Zhang W; Li G; Niu Y; Zhu X
    Biomater Sci; 2017 Sep; 5(10):2068-2078. PubMed ID: 28744533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation and development of MTH1 inhibitors for treatment of cancer.
    Warpman Berglund U; Sanjiv K; Gad H; Kalderén C; Koolmeister T; Pham T; Gokturk C; Jafari R; Maddalo G; Seashore-Ludlow B; Chernobrovkin A; Manoilov A; Pateras IS; Rasti A; Jemth AS; Almlöf I; Loseva O; Visnes T; Einarsdottir BO; Gaugaz FZ; Saleh A; Platzack B; Wallner OA; Vallin KS; Henriksson M; Wakchaure P; Borhade S; Herr P; Kallberg Y; Baranczewski P; Homan EJ; Wiita E; Nagpal V; Meijer T; Schipper N; Rudd SG; Bräutigam L; Lindqvist A; Filppula A; Lee TC; Artursson P; Nilsson JA; Gorgoulis VG; Lehtiö J; Zubarev RA; Scobie M; Helleday T
    Ann Oncol; 2016 Dec; 27(12):2275-2283. PubMed ID: 27827301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand retargeting by binding site analogy.
    Wiedmer L; Schärer C; Spiliotopoulos D; Hürzeler M; Śledź P; Caflisch A
    Eur J Med Chem; 2019 Aug; 175():107-113. PubMed ID: 31077996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects of MutT homolog 1 inhibitors in human bladder cancer cells.
    Lee JW; Lee S; Ho JN; Youn JI; Byun SS; Lee E
    Biosci Biotechnol Biochem; 2019 Dec; 83(12):2265-2271. PubMed ID: 31362565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.
    Lücking U; Wortmann L; Wengner AM; Lefranc J; Lienau P; Briem H; Siemeister G; Bömer U; Denner K; Schäfer M; Koppitz M; Eis K; Bartels F; Bader B; Bone W; Moosmayer D; Holton SJ; Eberspächer U; Grudzinska-Goebel J; Schatz C; Deeg G; Mumberg D; von Nussbaum F
    J Med Chem; 2020 Jul; 63(13):7293-7325. PubMed ID: 32502336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model.
    Moukengue B; Brown HK; Charrier C; Battaglia S; Baud'huin M; Quillard T; Pham TM; Pateras IS; Gorgoulis VG; Helleday T; Heymann D; Berglund UW; Ory B; Lamoureux F
    EBioMedicine; 2020 Mar; 53():102704. PubMed ID: 32151797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AuNP flares-capped mesoporous silica nanoplatform for MTH1 detection and inhibition.
    Gao W; Cao W; Sun Y; Wei X; Xu K; Zhang H; Tang B
    Biomaterials; 2015 Nov; 69():212-21. PubMed ID: 26298289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Chirality of Crizotinib on Its MTH1 Protein Inhibitory Activity: Insight from Molecular Dynamics Simulations and Binding Free Energy Calculations.
    Niu Y; Pan D; Shi D; Bai Q; Liu H; Yao X
    PLoS One; 2015; 10(12):e0145219. PubMed ID: 26677850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia.
    Pompsch M; Vogel J; Classen F; Kranz P; Iliakis G; Riffkin H; Brockmeier U; Metzen E
    BMC Cancer; 2018 Nov; 18(1):1190. PubMed ID: 30497423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival.
    Kawamura T; Kawatani M; Muroi M; Kondoh Y; Futamura Y; Aono H; Tanaka M; Honda K; Osada H
    Sci Rep; 2016 May; 6():26521. PubMed ID: 27210421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The druggability of intracellular nucleotide-degrading enzymes.
    Rampazzo C; Tozzi MG; Dumontet C; Jordheim LP
    Cancer Chemother Pharmacol; 2016 May; 77(5):883-93. PubMed ID: 26614508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.